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Abstract
Leber congenital amaurosis (LCA) is the earliest and most severe retinal degeneration (RD), and the most common cause of
incurable blindness diagnosed in children. It is occasionally the presenting symptom of multisystemic ciliopathies which
diagnosis will require a specific care of patients. Nineteen LCA genes are currently identified and three of them account for
both non-syndromic and syndromic forms of the disease. RD3 (LCA12) was implicated as a LCA gene based on the
identification of homozygous truncating mutations in two LCA families despite the screening of large cohorts of patients.
Here we provide a comprehensive survey of RD3 mutations and of their clinical expression through the screening of a
cohort of 852 patients originating worldwide affected with LCA or early-onset and severe RD. We identified three RD3
mutations in seven unrelated consanguineous LCA families - i.e., a 2 bp deletion and two nonsense mutations – predicted
to cause complete loss of function. Five families originating from the Southern Shores of the Mediterranean segregated a
similar mutation (c.112C.T, p.R38*) suggesting that this change may have resulted from an ancient founder effect.
Considering the low frequency of RD3 carriers, the recurrence risk for LCA in non-consanguineous unions is negligible for
both heterozygote and homozygote RD3 individuals. The LCA12 phenotype in our patients is highly similar to those of
patients with mutant photoreceptor-specific guanylate cyclase (GUCY2D/LCA1). This observation is consistent with the
report of the role of RD3 in trafficking of GUCYs and gives further support to a common mechanism of photoreceptor
degeneration in LCA12 and LCA1, i.e., inability to increase cytoplasmic cGMP concentration in outer segments and thus to
recover the dark-state. Similar to LCA1, LCA12 patients have no extraocular symptoms despite complete inactivation of both
RD3 alleles, supporting the view that extraocular investigations in LCA infants with RD3 mutations should be avoided.
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Introduction
Leber congenital amaurosis (LCA, MIM# 204000) is a group of
retinal dystrophies, which represents the most common cause of
blindness in childhood (10–18%) [1,2]. This disease is responsible
for blindness or profound visual deficiency at birth or in the first
months of life. Visual outcome ranges from a severe stationary
cone-rod disease with poor visual function (VA#light perception;
type I) to a progressive rod-cone dystrophy with measurable visual
acuity in the first decade of life (20/200#VA#60/200; type II)
[3]. Currently, 19 disease-causing genes have been mapped and/
or identified that account for 65–70% of the cases in ethnically
mixed populations [1,2]: GUCY2D (LCA1) [4], RPE65 (LCA2) [5],
SPATA7 (LCA3) [6], AIPL1 (LCA4) [7], LCA5 (LCA5) [8], RPGRIP1
(LCA6) [9,10], CRX (LCA7) [11,12], CRB1 (LCA8) [13], NMNAT1
(LCA9) [14–18], CEP290 (LCA10) [19], IMPDH1 (LCA11) [20],
RD3 (LCA12) [21], RDH12 (LCA13) [22,23], LRAT (LCA14) [24],
TULP1 (LCA15) [25], KCNJ13 (LCA16) [26], IQCB1 [27,28] and
MERTK [29]. Typically, LCA is an autosomal recessive condition.
Yet, some rare LCA cases have been ascribed to dominant CRX
[11,30–31] and IMPDH1 mutations [20].
The implication of LCA genes in retinal dystrophies of later-
onset is not uncommon (GUCY2D, RPE65, CRB1, TULP1, CRX,
RPGRIP1, AIPL1) [1,2]. Though less frequently, LCA genes may
be involved in severe and sometimes embryonically lethal
multisystemic conditions affecting the central nervous system,
kidneys, bones and/or the heart in addition to the retina (CEP290,
IQCB1) [32–33].
The clinical, genetic and molecular heterogeneity of LCA make
elucidating genotype-phenotype correlations a major medical issue
to predict the ophthalmologic course of the disease, to allow tailor-
made surveillance of extraocular systems and to direct genetic
studies. Significant genotype-phenotype correlations have been
reported for most LCA genes; for recent reviews see [1,34] but not
RD3 which mutations are amongst the rarest causes of the disease
with two homozygous mutations reported in two consanguineous
families [21,35].
Here, we report the results of an international study aimed at
delineating the clinical and molecular spectrum of RD3 mutations
in retinal dystrophies.
Patients and Methods
Patients and Controls
A total of 852 unrelated patients ascertained in -or addressed to-
10 Centers in Europe (France, Germany, Italy, the Netherlands
and Spain), North-America (The United States and Canada) and
China were considered in this study including 574 LCA probands
who have not had disease-causing mutations identified in the
known LCA genes, 96 probands affected with autosomal recessive
early-onset severe retinal dystrophies (EOSRD), 150 with autoso-
mal recessive retinitis pigmentosa (RP) and 32 with other retinal
dystrophies. The ethnicity of patients and diagnoses are shown in
Table 1. Written consents were obtained from participants or
legally authorized representatives at each participating Center.
The study was conducted at all sites in strict adherence to the
tenets of the Declaration of Helsinki and was approved by the
respective National Institutional Review Boards: Including the
Comite´ de Protection des Personnes Ile-de-France II, the McGill
University Health Centre Research Institute, the Academic
Medical Centre of Amsterdam The Netherlands,the Ethics
Committee of the Second University of Naples, the Bioethics
Committee of the University of Barcelona, the Ethics Committee
of Rotterdam and Nijmegen (MEC-2001-23, MEC-2005-371, and
MEC-2010-359), the Baylor College of Medicine Institutional
Review Board, the Ethics committee of the Medical Faculty of
University of Tubingen and the Zhongshan Ophthalmic Center of
Sun Yat-sen University.
Screening of RD3
Samples were collected and screened for RD3 mutations
independently. Patients of all cohorts but one were screened by
direct sequencing using intronic primers designed to amplify the
two RD3 coding exons and intron-exon boundaries. The 313 LCA
probands of the University of Iowa Carver College cohort were
screened by single strand conformation using as controls 151
normal individuals. PCR, direct sequencing and SSCP conditions,
as well as primer sequences are available on request.
A variant was predicted to be pathogenic when it showed
familial cosegregation with the disease and absence in control
individuals and when it was predicted to be damaging by Align
DGVD, Polyphen-2, SIFT, SpliceSiteFinder-like, MaxEntScan,
Table 1. Cohorts of patients affected with various retinal dystrophies screened for RD3 mutations.
Origin Number patients Ethnicity Screening methodology
LCA (n=574) Central America 10 Mexican 1
North America 513 Unspecified mixed 1,2
China 78 Han Chinese 1
Europe
France 190 Mixed population 1
Germany 1 Turkish origin
Italy 90 Italian 1
Spain 5 Spanish 1
EOSRD (n=96) Europe (The Netherlands) 96 Mostly Dutch patients 1
RD* (n=182) Europe (Italy) 150 Italian 1
China 11+21** Han Chinese 1
*Retinal dystrophies including cone/cone-rod dystrophies and unclassified RDs;
**Patients with blindness or severe visual deficiency but ERG data unavailable.1 Direct sequencing and 2 SCCP screening of the two coding exons and intron-exon
boundaries.
doi:10.1371/journal.pone.0051622.t001
RD3 Mutations and the Associated Phenotype
PLOS ONE | www.plosone.org 2 January 2013 | Volume 8 | Issue 1 | e51622
NNSPLICE and Human Splicing Finder available through the
Alamut Interpretation Software 2.0.
Linkage disequilibrium analysis
Haplotype analysis was performed using 4/5 families segregat-
ing the c.112C.T mutation of the RD3 gene. Microsatellite
markers distributed over a 12.6 Megabases (Mb) interval spanning
the RD3 locus on chromosome 1q32.2-q41 (according to the
UCSC Genome Browser GRCh37/hg19 assembly) were used for
haplotype analysis. Microsatellite markers included (from telomere
to centromere): AFMB347YA5 (D1S2782), AFM281YG1
(D1S471), AFM310VB1 (D1S491), AFM108YA3 (D1S205),
AFM179XG5 (D1S414) AFMC011YD5 (D1S2810), AFM-
B342YG1 (D1S2780), AFM203ZB6 (D1S425), AFMA127WB5
(D1S505), AFM297XC1 (D1S2827), AFM058XG9 (D1S2880).
Amplified fragments were electrophoresed on an automatic
sequencer (ABI 3100, Applied Biosystems, Foster City, CA) and
analyzed using the GeneScan Analysis 3.7 and Genotyper
softwares. For each marker, the heterozygote frequency and the
size range of alleles were either available from Genethon Linkage
Map [36]. The size of the alleles carried by the members of
families NEM1, NEM2, NEM3 and NEM4 was determined
relative to the reference DNA sequence obtained from the Centre
d’Etude du Polymorphisme Humain (CEPH).
The degree of linkage disequilibrium and the estimation of the
age of the mutation were obtained as described previously [37].
Results
RD3 mutations, changes of uncertain pathogenicity and
polymorphisms
Three novel mutations were detected in seven apparently
unrelated LCA families (Table 2). Two out of the three mutations
affect codon c.136–138 (exon 2), which encodes the glutamic acid
at position 46. The first one consists of a 2 bp deletion expected to
result in the substitution of the glutamic acid into an alanine and
the apparition of a premature stop codon, 26 amino-acids
downstream (c.137–138delAG; p.E46Afs*83). Sequence analysis
indicates that the microdeletion is not expected to alter the splicing
of the messenger RNA (Human Splicing Finder, SpliceSiteFinder-
like, MaxEntScan, NNSplice). The second change consists of a G
to T transversion expected to change the glutamic acid at position
46 by a signal of termination of the translation (c.136G.T,
p.E46*) and/or to create a cryptic donor-splice site which use
would lead to the production of a 141-aa protein lacking aa 46–99
and thus the C terminus of the predicted coiled coil domain
(Human Splicing Finder score 71.2 vs exon 2 acceptor site 96.7).
The third mutation occurred on the nt112–113 CpG doublet
(c.112C.T). It is expected to change the arginine at position 38 by
a signal of termination of the translation (p.R38*) and/or to create
a cryptic donor-splice site which use would result in the production
of a 132-aa protein lacking amino acids 38–99 including the
putative coiled-coil domain (Human Splicing Finder, SpliceSite-
Finder-like, MaxEntScan). All three mutations are expected to
truncate the RD3 protein. It is thus possible that the mutant
mRNAs may be prone to nonsense-mediated decay. It is
interesting to note that the E46 position may be hypermutable
(2 different mutations affecting the codon).
All three mutations segregated with the disease in families and
were neither identified in controls nor reported elsewhere.
The c.112C.T mutation was shared by 5/7 of the families
segregating RD3 mutations. Indirect studies at the RD3 locus were
performed on 4/5 families indicate that the two Moroccan families
and the Turkish family share a small 1 Mb-long common
haplotype that differed in the Libanese family (Figure 1).
Haplotype analyses and Bayesian calculations allowed estimating
that the founder mutation might have occurred 100–150
generations ago.
In addition to RD3 mutations, we identified a A to T
transversion at position 146 of the cDNA resulting into the
substitution of an asparagine into an isoleucine at position 49 of
the protein (c.146A.T; N49I). This variant that changes a basic
amino acid into an uncharged residue is predicted to be
deleterious by the SIFT, Polyphen-2 and AlignGCVD programs.
The change was identified neither in 200 control individuals nor in
databases listing SNPs. This change was identified in a heterozy-
gous state in an isolated case born to non-consanguineous parents
(Table 3).
Finally, 13 polymorphic variants were identified, 3/13 of which
were not reported elsewhere (Table 4). All three changes (2/3 non-
conservative) were predicted to be benign by the Alamut
Interpretation Software.
Phenotype of patients harboring RD3 mutations
The natural history of the disease and clinical data available of
patients harboring RD3 mutations were reviewed (11 patients in 7
families; mean age = 10.2 yrs; age range 1–31 yrs, Table 2).
Patients consistently presented with congenital nystagmus, low
vision, sluggish pupillary reflexes, absence of ocular pursuit since
birth, early-onset and long-lasting digito-ocular signs of Fran-
ceschetti, photoaversion (one exception) and mild to moderate
hyperopia. Visual acuity, when measurable, was reduced to
counting fingers, hand-movements or light perception. Reduced
visual acuity hindered recording color vision and visual field
(Table 2). Fundus consistently showed dull retina with salt and
pepper aspect, thin retinal vessels and an early macular
rearrangement (maculopathy, Figure 2). Spectral Domain OCT
imaging was available in the Tu¨bingen case. The photoreceptor
layer was missing, the inner segment/outer segment border was
diminished and an increased backscatter from the choroid was
observed due to RPE-atrophy. On the other hand, inner retinal
layers seemed to show a rather preserved structure. Fundus
autofluorescence (FAF) was severely reduced, a proper image
could not be taken.
Discussion
Until this report, the implication of RD3 in retinal dystrophies
was based on the following three studies: homozygosity for
truncating mutations in two consanguineous LCA families [2/59;
21,35], two naturally occurring models of autosomal recessive
EOSRD, the retinal degeneration 3 (rd3) mouse [21,38] and the rod-
cone dystrophy 2 (rcd2) collie [39–40]. The identification in our report
of three mutations expected to truncate the protein in seven
additional families gives strong support to the role of RD3 in LCA.
Yet, the mutation rate obtained in a very large cohort of LCA
cases originating worldwide (7/574 LCA cases excluding other
LCA genes) and consistent identification of homozygous mutations
in consanguineous families [21,35, present study], support the very
low frequency of heterozygous RD3 carriers in the general
population.
RD3 encodes an evolutionary conserved basic protein of 195
amino acids that is preferentially expressed in the retina [41]. In
the mouse, it exhibits increasing expression through early
postnatal development. In adulthood, it is highly expressed in
cone and rod outer segments where it co-localizes with retinal-
specific guanylate cyclases, GC1 and GC2, respectively. In the
cones, RD3 has been shown to mediate the export of GC1 from
RD3 Mutations and the Associated Phenotype
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the endoplasmic reticulum to endosomal vesicles with the C
terminus of GC1 being required for RD3 binding [21,41–42]. The
loss of GC1 and GC2 in the photoreceptors of the rd3 mouse
which express a truncated unstable rd3 protein resulting from the
p.R107* mutation, is consistent with a role of the protein in the
trafficking of GC2 in rods as well. As a consequence, like the
double GC1/GC2 knock-out, the complete inactivation of both
rd3 alleles is expected to preclude cGMP synthesis in both rod and
cone outer segments and to hinder recovery of the dark state after
light stimulation [21,42–43]. Consistently, the retina of the animal
develops normally but both rod and cone photoreceptors start
degenerating by postnatal day 14 - i.e. when eyes open – and the
degeneration is almost complete by the age of 2–4 months
[21,38,44]. Similarly, the rd3 frameshift mutation (p.Pro139Alafs*)
of the rcd2 collie [40] is likely to produce an unstable, non-
functional rd3 protein leading to the loss of GC expression and
trafficking. The retina of homozygous rcd2 dogs develops almost
normally, by the age of 2–2.5 months, the outer segments of both
rods and cones are completely lost, with rods degenerating faster
than cones [45].
Interestingly, these data which support a common mechanism
of photoreceptor degeneration in rd3 and GC double knock-out
mice [43] are consistent with the phenotypic overlap between
LCA12 and LCA1. Indeed, the review of the natural history and
clinical data of our patients and that of the two original RD3
families [21,35] delineate a homogeneous phenotype unambigu-
ously consistent with the diagnosis of congenital and dramatically
severe cone-rod dystrophy (LCA type I) originally described in
LCA1 patients harboring GUGY2D mutations [3].
RD3 mutations identified thus far are expected to truncate the
RD3 protein [21,35, present study]. It is tempting to hypothesize
that similar to several other LCA genes, mutations with a milder
effect on the protein structure and/or function may be responsible
for milder phenotypes; for recent reviews see [1,2]. However, none
of the unrelated patients affected by various retinal dystrophies of
later-onset and/or severity in our cohort (n = 278) and the other
two reported series (n = 907) [21,35,40] exhibited disease-causing
RD3 mutations. This finding is consistent with the LCA type I-
specific involvement of RD3 mutations. Indeed, of the LCA genes,
most genes involved in EOSRD and RP account for LCA type II
[1].
Figure 1. Pedigree structure of the 4/5 families segregating the c.112C.T mutation of the RD3 gene with haplotypes reconstruction
for informative markers on chromosome 1q32.2-q41. Black circles (women) and squares (men) indicate affected members. Chromosomal
positions of SNP and microsatellite markers are indicated in Mega base pairs (Mb) according to the UCSC Genome Browser GRCh37/hg19 assembly.
Common haplotypes in families NEM1, NEM2 and in families NEM1, NEM2, NEM3 are shared with dotted and solid lines, respectively. NA not available.
doi:10.1371/journal.pone.0051622.g001
Table 3. RD3 Changes of uncertain pathogenicity.
Position Mutation type Mutation
Predicted effect
on protein
Conservation of the
mutant aa
Predicted effect (SIFT,
Polyphen-2, AlignGCVD) Remarks
Exon 2 Missense c.146A.T p.N49I Low Deleterious 1/200 patient (European
descent, single heterozygosity)
doi:10.1371/journal.pone.0051622.t003
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Until now, four LCA genes account for congenital cone-rod
dystrophy (LCA type I): GUCY2D [3], RPGRIP1 [21], CEP290
[46] and RD3 [present study]. Refraction may represent a
distinctive feature in LCA type I since patients with GUCY2D
mutations consistently have high hypermetropia (.+7) with
frequent enophthalmia [3,25] whereas those who harbor
RPGRIP1, CEP290 or RD3 mutations present with lower or no
hyperopia ([25,46], present study). On the other hand, several
population-specific mutations were identified in LCA type I genes.
In Mediterranean countries where CEP290 mutations are
particularly uncommon [46–47], high frequencies of GUCY2D
mutations resulting from founder effects have been reported
[25,37,48]. With the present report, RD3 mutations were
identified in nine consanguineous families, 6/9 of which originate
from Mediterranean countries. Five out of the six families
harbored the c.112C.T mutation. Considering, the very low
frequency of this mutation in populations with different genetic
backgrounds, it is unlikely that it results from the recurrent
deamination of the cytosine of the nt112–113 CpG doublet [49].
Besides, indirect studies at the RD3 locus were consistent with the
transmission of an ancient founder mutation that occurred in the
Mediterranean region. The prevalence of a RD3 mutation in
Mediterranean countries allows us to improve the diagnostic
flowchart drawn to direct the molecular analysis of LCA type I
genes previously reported [1,2]. In LCA type I patients originating
from this region with moderate or no hyperopia, RD3 should be
screened for mutations first, before GUCY2D, RPGRIP1 and
CEP290.
With respect to genetic counseling, our data that support a
dramatically low RD3 carrier frequency in the general population
indicate that the genetic risk in the case of the union between an
affected person harboring RD3 mutations and an individual of the
general population with no family history of LCA is negligible.
Unions between affected persons with LCA and or between LCA
and RP patients are not uncommon. The identification of RD3
mutations in one spouse must prompt the search for RD3
mutations, only when the other spouse is affected with LCA type
I. Indeed, if the spouse is affected with LCA type II or autosomal
recessive RP of later-onset, the genetic counseling can straight-
away be reassuring.
The comprehensive survey of RD3 mutations in large cohorts of
patients accurately phenotyped by referent clinicians has major
clinical implications. Most LCA genes have demonstrated a
preferential or specific retinal expression [1,2]. Consistently, their
alterations account for isolated forms of the disease. Yet,
increasing numbers of disease-causing genes display greater and
more wide-spread patterns of expression including CEP290 which
mutations are either responsible for non-syndromic LCA or a
range of syndromic forms of the disease; for review see [32]. On
the other hand, mutations in the IQCB1 gene at the NPHP5 locus
have been shown to cause a form of Senior-Loken syndrome
characterized by a congenital retinal dystrophy associated with a
renal dysfunction of highly variable age of onset (1st to 5th decade)
[27,28,33]. These recent findings support the view that the
identification of the disease gene may be a valuable prognostic tool
in young individuals affected with LCA. With regard to RD3, it is
worth noting that none of the patients reported here whose ages
ranged from 2 to 31 had renal failure, neurological symptoms or
intellectual disability. Owing to the retina-specific pattern of
Table 4. RD3 Coding SNPs.
Position Polymorphism type Change
Predicted effect on
protein Rs numnber Reference
Exon 2 Non-conservative c.16T.C p.W6R rs35649846 dbSNP
Exon 2 Non-conservative c.69G.C p.E23D rs34422496 dbSNP
Exon 2 Non-conservative c.83C.T p.T28M rs61740157 dbSNP
Exon 2 Conservative c.84G.A p.T28T rs61740158 dbSNP
Exon 2 Non-conservative c.101C.T p.T34M - This study
Exon 2 Non-conservative c.103G.A p.G35R rs34049451 dbSNP
Exon 2 Non-conservative c.139C.T p.R47C rs34049451 dbSNP
Exon 2 Non-conservative c.202C.T p.R68W - Friedman et al. 2006
Exon 2 Conservative c.235T.C p.L79L rs35937732 dbSNP
Exon 3 Conservative c.498C.T p.I166I - This study
Exon 3 Non-conservative c.500G.A p.R167K rs74782684 dbSNP
Exon 3 Non-conservative c.511G.A p.E171K - This study
Exon 3 Non-conservative c.584A.T p.D195V - Friedman et al. 2006; This
study
Novel non-conservative changes were regarded as polymorphisms when they did not segregate with the disease in patients and/or were found in control individuals.
References: 1:http//www.ncbi.nlm.nih.gov/SNP/; 2: Friedman et al. 2006. All Sequence change data are based on the RefSeq cDNA sequence NM_183059.2.
doi:10.1371/journal.pone.0051622.t004
Figure 2. Fundus photographs of the affected person FJC/F
(Table 2A). The proband has poor vision since birth with nystagmus
and atrophic lesions in the macular area.
doi:10.1371/journal.pone.0051622.g002
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expression of RD3, it is likely that the disease may remain
restricted to this tissue. In these patients, anxiogenic and expensive
extraocular explorations must not be systematically prescribed.
The recovery of the dark state in the retina through GC-
mediated increase in cytoplasmic cGMP concentration in photo-
receptor outer segments is a sine qua none condition to maintain
living and functional rod and cone cells. Our knowledge regarding
the mechanisms of this complex process - which alteration
accounts for ,17% of LCA cases - are incomplete. In particular,
most of the molecular players and disease mechanisms of light-
driven trafficking between the inner and outer segments of
photoreceptors are unknown. Interestingly, although RD3 alter-
ations are quite uncommon, their description in man and animal
models unraveled a crucial protein for GC expression and
trafficking in photoreceptors. Further studies designed to identify
RD3 partners will hopefully contribute to the deciphering of
mechanisms for dark-state recovery and will hopefully allow
uncovering some of the yet unidentified LCA causing genes.
Finally, it is worth remembering that the success of gene
replacement and drug therapy to restore vision in naturally
occurring RPE652/2 Briard dogs has paved the way for the
development of gene and drug therapy for a broad range of eye
disorders and made large dogs the species of choice for these
developments; for review see [50]. In this context, although RD3
mutations are uncommon causes of LCA, the availability of
naturally occurring rd3 animal models, among which a large dog
(collie), it is likely that gene and drug therapy protocols will be
developed to treat patients with RD3 mutations.
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